Surmodics Inc (OQ:SRDX)

Business Focus: Medical Equipment, Supplies & Distribution

Feb 27, 2024 08:00 am ET
Surmodics to Participate in Upcoming Investor Conferences in March and April
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor conferences:
Feb 01, 2024 07:00 am ET
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2023, and updated its financial guidance for fiscal year ending September 30, 2024.
Jan 22, 2024 07:30 am ET
Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Kn
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced successful early clinical use of the company’s Pounce™ LP (Low Profile) Thrombectomy System. The Pounce LP Thrombectomy System, which received U.S. Food and Drug Administration (FDA) clearance in June 2023, is currently in limited market evaluation (LME), with full commercial launch planned following completion of the LME.
Jan 16, 2024 07:30 am ET
Surmodics to Host Virtual Annual Meeting of Shareholders
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 8, at 4 p.m. CT (5 p.m. ET), as a virtual meeting.
Jan 16, 2024 07:30 am ET
Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first quarter of fiscal year 2024 financial results will be released before the market opens on Thursday, February 1.
Nov 16, 2023 07:30 am ET
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that 24-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon (DCB) was presented at the 50th annual VEITH Symposium in New York, New York.
Nov 16, 2023 07:30 am ET
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the 50th Annual VEITH Symposium in New York, New York.
Nov 14, 2023 04:05 pm ET
Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the 35th Annual Piper Sandler Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from November 28-30, 2023. Management will present on Tuesday, November 28, at 8:30 a.m. ET (7:30 a.m. CT).
Nov 08, 2023 07:30 am ET
Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2023, and introduced its financial guidance for the fiscal year ending September 30, 2024.
Nov 07, 2023 07:30 am ET
Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Professor Ramon Varcoe will present 24-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon (DCB). The session will be held on Wednesday, November 15th, at the 50th annual VEITH Symposium in New York, New York.
Nov 07, 2023 07:30 am ET
Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial will be presented at the upcoming 50th Annual VEITH Symposium in New York, New York.
Oct 31, 2023 07:30 am ET
Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications
Surmodics, Inc. (NASDAQ: SRDX), the global leader in medical device coating technologies, announced the commercial launch of its most advanced hydrophilic medical device coating technology, Preside™ hydrophilic coatings.
Oct 10, 2023 07:30 am ET
Surmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that fourth quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, November 8.
Aug 15, 2023 10:20 am ET
Sidoti Events, LLC’s Virtual August Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Aug 09, 2023 05:05 pm ET
Surmodics to Participate in Upcoming Investor Conferences in August
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor conferences:
Aug 02, 2023 07:31 am ET
Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023.
Jul 12, 2023 07:30 am ET
Surmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that third quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, August 2.
Jun 20, 2023 06:30 am ET
Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the receipt of U.S. Food and Drug Administration (FDA) approval for the SurVeil™ drug-coated balloon (DCB).
Jun 14, 2023 07:30 am ET
Surmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy System
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce™ LP (Low Profile) Thrombectomy System.
May 25, 2023 04:05 pm ET
Surmodics to Participate in the Jefferies Healthcare Conference on June 8
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the Jefferies Healthcare Conference, which is being held in New York, NY, from June 7-9, 2023. Management will present on Thursday, June 8, at 1:30 p.m. ET (12:30 p.m. CT).
Apr 26, 2023 07:00 am ET
Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023.
Apr 20, 2023 07:05 am ET
Surmodics Announces First Patient Enrolled in PROWL Registry Study Using the Pounce™ Thrombectomy System
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first patient in PROWL, the Pounce™ Thrombectomy System Retrospective Registry.
Apr 19, 2023 07:30 am ET
Surmodics to Report Second Quarter of Fiscal 2023 Financial Results on April 26
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, April 26.
Apr 19, 2023 07:00 am ET
Surmodics Announces Successful First Patient Use of Sublime™ Radial Access Microcatheter Designed for the Periphery
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr. Ankur Lodha, Lafayette, La., and Dr. Pradeep Nair, Houma, La., are the first physicians to use the company’s Sublime™ radial access microcatheter. Drs. Lodha and Nair are interventional cardiologists at the Cardiovascular Institute of the South.
Apr 11, 2023 08:30 am ET
Surmodics to Participate in the 22nd Annual Needham Virtual Healthcare Conference on April 20
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the 22nd Annual Needham Virtual Healthcare Conference, which is being held from April 17-20, 2023. Management will present on Thursday, April 20, at 10:15 a.m. ET (9:15 a.m. CT).
Mar 28, 2023 09:25 am ET
Surmodics Provides Regulatory Update on its Strategy to Submit an Amended Premarket Approval Application for the SurVeil™ Drug-Coated Balloon
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it has received formal feedback from the Food and Drug Administration (FDA; the Agency) related to its proposed approach to submit an amended premarket approval (PMA) application for the SurVeil™ drug-coated balloon (DCB).
Mar 20, 2023 02:00 pm ET
Sidoti's Small-Cap Virtual March Conference
NEW YORK, NY / ACCESSWIRE / March 20, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 22-23, 2023. The links can also be found at www.sidoticonference.com/events.
Mar 19, 2023 10:54 pm ET
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially misleading...
Mar 14, 2023 08:25 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially...
Mar 09, 2023 07:20 pm ET
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially...
Mar 08, 2023 08:30 am ET
Surmodics to Participate in Upcoming Investor Conferences in March
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor conferences:
Mar 03, 2023 01:05 pm ET
SRDX NOTICE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially...
Mar 01, 2023 04:57 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surmodics, Inc. - SRDX
Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Feb 23, 2023 07:40 pm ET
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially misleading...
Feb 20, 2023 03:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surmodics, Inc. - SRDX
Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Feb 15, 2023 08:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Surmodics, Inc. – SRDX
Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Feb 14, 2023 08:32 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surmodics, Inc. - SRDX
Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Feb 14, 2023 06:43 pm ET
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially misleading...
Feb 09, 2023 07:51 pm ET
NATIONALLY RANKED ROSEN LAW FIRM Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Surmodics may have issued materially...
Feb 06, 2023 10:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surmodics, Inc. - SRDX
NEW YORK, Feb. 6, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. ("Surmodics" or the "Company") (NASDAQ: SRDX).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Feb 06, 2023 04:05 pm ET
Surmodics Reports First Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2022, and updated its financial outlook for its fiscal year ending September 30, 2023.
Feb 04, 2023 04:02 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surmodics, Inc. - SRDX
Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jan 31, 2023 08:30 am ET
Surmodics to Host Virtual Annual Meeting of Shareholders
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 9, at 4 p.m. CT (5 p.m. ET), as a virtual meeting.
Jan 26, 2023 09:45 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surmodics, Inc. ("Surmodics" or "the Company") (NASDAQ:SRDX) for violations of the securities laws.
Jan 26, 2023 08:30 am ET
Surmodics to Report First Quarter of Fiscal 2023 Financial Results on February 6
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first quarter of fiscal year 2023 financial results will be released after the market closes on Monday, February 6.
Jan 25, 2023 09:30 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofSurmodics, Inc. ("Surmodics" or "the Company") (NASDAQ:SRDX) for violations of the securities laws.
Jan 25, 2023 10:30 am ET
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surmodics, Inc. ("Surmodics" or "the Company") (NASDAQ:SRDX) for violations of the securities laws.
Jan 24, 2023 02:00 pm ET
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surmodics, Inc. ("Surmodics" or "the Company") (NASDAQ:SRDX) for violations of the securities laws.
Jan 23, 2023 07:15 pm ET
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 23, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofSurmodics, Inc. ("Surmodics" or "the Company") (NASDAQ:SRDX) for violations of the securities laws.
Jan 23, 2023 08:15 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or “the Company”) (NASDAQ:
Jan 20, 2023 09:04 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surmodics, Inc. (“Surmodics” or “the Company”) (NASDAQ:
Jan 20, 2023 06:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surmodics, Inc. - SRDX
NEW YORK, Jan. 20, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Surmodics, Inc. ("Surmodics" or the "Company") (NASDAQ: SRDX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jan 20, 2023 11:48 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Surmodics, Inc. (SRDX) Investigation
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Surmodics, Inc. (“Surmodics” or the “Company”) (NASDAQ: SRDX). Investors who purchased Surmodics securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg
Jan 19, 2023 03:43 pm ET
SRDX EQUITY ALERT: Rosen Law Firm Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Surmodics Inc. (NASDAQ: SRDX) resulting from allegations that Li Auto may have issued materially misleading business information to the investing public.
Jan 19, 2023 08:30 am ET
Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference
Surmodics, Inc. (NASDAQ:SRDX) (the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the differentiated capabilities of its crystalline drug release (CDR) platform for sirolimus-coated balloons (SCBs) were discussed in connection with 12-month data from the Company’s SWING trial at the 35th annual International Symposium on Endovascular Therapy (ISET) in Miami, Florida. The SWING trial is a first-in-human feasibility study of the Company’s Sundance™ SCB.
Jan 19, 2023 07:00 am ET
Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has received a letter from the U.S. Food and Drug Administration (FDA; the Agency) related to its premarket approval (PMA) application for the SurVeil™ drug-coated balloon (DCB).
Jan 16, 2023 08:30 am ET
Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Professor Ramon Varcoe will present 12-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon (DCB). The session will be held on Wednesday, January 18, at the 35th annual International Symposium on Endovascular Therapy (ISET) conference in Miami, Florida. Professor Varcoe will also discuss the differentiated capabilities of the Surmodics crystalline drug
Nov 17, 2022 08:30 am ET
Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium
Surmodics, Inc. (NASDAQ:SRDX) (the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 12-month data from the SWING Trial, a first-in-human study of the Company’s Sundance™ Sirolimus drug-coated balloon (DCB) was presented at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium) in New York City.
Nov 11, 2022 08:30 am ET
Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Professor Ramon Varcoe will present 12-month data from the SWING Trial, a first-in-human study of the safety and efficacy of the Sundance™ Sirolimus Drug-Coated Balloon (DCB). The session will be held on Wednesday, November 16, at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium) in New York City.
Nov 09, 2022 07:00 am ET
Surmodics Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Financial Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2022, and introduced its financial outlook for the fiscal year ending September 30, 2023.
Nov 02, 2022 08:30 am ET
24-Month Data from Surmodics’ TRANSCEND Trial Presented at VIVA 2022 Conference
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 24-month data from its TRANSCEND clinical trial has been presented at the Vascular InterVentional Advances (VIVA) annual conference in Las Vegas.
Oct 28, 2022 07:30 am ET
Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical devices and in vitro diagnostic technologies to the healthcare industry, today announced that fourth quarter and fiscal year 2022 financial results will be released before the market opens on Wednesday, November 9th.
Oct 26, 2022 08:30 am ET
Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 24-month data from its TRANSCEND clinical trial will be presented at the upcoming Vascular InterVentional Advances (VIVA) annual conference in Las Vegas.
Oct 17, 2022 08:30 am ET
Surmodics Announces New Credit Facilities Providing up to $125 Million in Financing
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered into a new, five-year credit agreement with MidCap Financial (“MidCap”), comprised of up to $100 million in term loans and a $25 million revolving credit facility.
Oct 11, 2022 08:30 am ET
6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 6-month data from its SWING first-in-human (FIH) study of the company’s Sundance™ Sirolimus drug-coated balloon (DCB) was shared at the Amputation Prevention Symposium (AMP) in Lugano, Switzerland.
Oct 07, 2022 08:30 am ET
6-Month Data from the Surmodics SWING First-in-Human Study to be Presented at AMP Europe
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Professor Ramon Varcoe will present 6-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon. The session will be held on Tuesday, October 11, at the Amputation Prevention Symposium (AMP) in Lugano, Switzerland.
Aug 23, 2022 08:30 am ET
Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical devices and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will make a presentation to the investment community at the Gilmartin Emerging Growth Company Showcase on Wednesday, August 31, 2022 at 12:30 p.m. ET. A live audio webcast of the presentation will be available at the following link:
Jul 27, 2022 07:30 am ET
Surmodics Reports Third Quarter Fiscal 2022 Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 third quarter ended June 30, 2022 and updated its financial outlook for its fiscal 2022.
Jul 19, 2022 08:30 am ET
Surmodics to Webcast Third Quarter Fiscal 2022 Earnings Conference Call on July 27
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2022 conference call on Wednesday, July 27, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release before the market opens that morning.
Jun 01, 2022 08:30 am ET
Surmodics to Present at Jefferies Healthcare Conference
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies 2022 Healthcare Conference in New York City on Thursday, June 9, 2022, at 3:30 p.m. ET. A live audio webcast of the presentation will be available at the following link:
Apr 27, 2022 07:30 am ET
Surmodics Reports Second Quarter Fiscal 2022 Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 second quarter ended March 31, 2022 and updated its financial outlook for its fiscal 2022.
Apr 27, 2022 07:15 am ET
Pounce™ Thrombectomy System First-in-Human Data Show 100 Percent Technical Success in Early Cases
Surmodics, Inc. (NASDAQ : SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that its Pounce™ Thrombectomy System achieved 100 percent technical success in 20 First-in-Human (FIH) procedures. The FIH data was presented Tuesday by Dr. Gary Ansel at the Charing Cross International Symposium in London.
Apr 25, 2022 08:25 am ET
Dr. Gary Ansel to Present Pounce™ Thrombectomy System First-in-Human Data at Charing Cross Symposium
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Gary Ansel, MD, will present First-In-Human (FIH) data on the company’s Pounce™ Thrombectomy System on Tuesday, April 26, at the Charing Cross International Symposium in London.
Apr 19, 2022 08:30 am ET
Surmodics to Webcast Second Quarter Fiscal 2022 Earnings Conference Call on April 27
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2022 conference call on Wednesday, April 27, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release before the market opens that morning.
Feb 04, 2022 08:30 am ET
Surmodics to Host Virtual Annual Meeting of Shareholders
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 10, at 4:00 p.m. CT (5:00 p.m. ET), as a virtual meeting. Sue Knight, board chair, will lead the meeting, and Gary Maharaj, chief executive officer, will provide a brief update on business and key strategic initiatives underway at the Company.
Feb 03, 2022 07:30 am ET
Surmodics Reports First Quarter Fiscal 2022 Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 first quarter ended December 31, 2021.
Jan 26, 2022 08:30 am ET
Surmodics to Webcast First Quarter Fiscal 2022 Earnings Conference Call on February 3
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2022 conference call on Thursday, February 3, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release before the market opens that morning.
Jan 18, 2022 07:30 am ET
Sidoti Winter Virtual Small Cap Investor Conference
NEW YORK, NY / ACCESSWIRE / January 18, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Small Cap Virtual Conference taking place Wednesday and Thursday, December 19th-20th, 2022. The links can also be found at www.sidoticonference.com/events.
Jan 11, 2022 08:35 am ET
Surmodics to Present at Sidoti & Company Virtual Investor Conference
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will present and host one-on-one meetings with investors at the Sidoti Winter Virtual Investor Conference on Wednesday, January 19, 2022. A live audio webcast of the presentation will be available by going to the investor relations portion of the Company’s website at
Jan 05, 2022 07:00 am ET
Miromatrix Announces Two New Board Members
Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced the expansion of the board and appointment of two...
Nov 10, 2021 07:30 am ET
Surmodics Reports Fourth Quarter Fiscal 2021 Results and Issues Fiscal 2022 Revenue and EPS Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 fourth quarter ended September 30, 2021 and provided its financial outlook for its fiscal 2022.
Nov 02, 2021 08:30 am ET
Surmodics to Webcast Fourth Quarter Fiscal 2021 Earnings Conference Call on November 10
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2021 conference call on Wednesday, November 10, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release before the market opens that morning.
Sep 29, 2021 08:15 am ET
Surmodics Announces Successful First Patient Uses of Sublime™ Radial Access .018 RX PTA Dilatation Catheter
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful first clinical uses of the Sublime™ Radial Access .018 RX PTA Dilatation Catheter.
Aug 04, 2021 07:30 am ET
Surmodics Reports Third Quarter Fiscal 2021 Results and Updates Fiscal 2021 Revenue and EPS Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 third quarter ended June 30, 2021 and updated its financial outlook for its fiscal 2021.
Jul 29, 2021 08:30 am ET
Surmodics Announces Successful First Patient Use of Pounce™ Thrombectomy System
The procedure, completed last month, involved a patient presenting with increasing pain in the left leg and was diagnosed with an occluded superficial femoral artery (SFA). Three passes of the Pounce device removed 30 cm of subacute thrombus and blood flow was successfully restored. Eight additional cases have since been performed in the U.S., with positive outcomes reported following each procedure.
Jul 27, 2021 08:30 am ET
Surmodics to Webcast Third Quarter Fiscal 2021 Earnings Conference Call on August 4
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2021 conference call on Wednesday, August 4, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release before the market opens that morning.
Jul 06, 2021 08:05 am ET
Surmodics Builds Thrombectomy Portfolio with Acquisition of Vetex Medical Limited
Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that it has acquired privately held Vetex Medical Limited. The Galway, Ireland based medical device developer and manufacturer has focused exclusively on venous clot removal solutions. The transaction expands Surmodics’ thrombectomy portfolio with a second U.S. Food and Drug Administration (FDA) 510(k)-cleared device, the ReVene™ Thrombectomy Catheter.
Apr 28, 2021 07:30 am ET
Surmodics Reports Second Quarter Fiscal 2021 Results and Issues Fiscal 2021 Revenue and EPS Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 second quarter ended March 31, 2021 and provided its financial outlook for its fiscal 2021.
Apr 20, 2021 08:30 am ET
Surmodics to Webcast Second Quarter Fiscal 2021 Earnings Conference Call on April 28
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2021 conference call on Wednesday, April 28, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release before the market opens that morning.
Apr 01, 2021 08:30 am ET
Surmodics Announces Successful First Patient Uses of Two Sublime™ Radial Access Platform Devices
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful first uses with patients for two devices within its Sublime™ Radial Access Platform: the Sublime™ Radial Access Guide Sheath and Sublime Radial Access .014 RX
Mar 23, 2021 07:30 pm ET
Sidoti Virtual Investor Conference
Presentation Times and Weblinks Released for Over 125 Presenting Companies
Mar 17, 2021 04:05 pm ET
Surmodics to Present at Sidoti & Company Virtual Investor Conference
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will make a presentation at the Sidoti & Company Virtual Investor Conference on Thursday, March 25, at 10:00 a.m. ET (9:00 a.m. CT).
Feb 09, 2021 07:30 am ET
Surmodics Reports First Quarter Fiscal 2021 Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 first quarter ended December 31, 2020.
Feb 04, 2021 08:30 am ET
Surmodics to Host Virtual Annual Meeting of Shareholders
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 11, at 4:00 p.m. CT (5:00 p.m. ET), as a virtual meeting.
Feb 01, 2021 08:30 am ET
Surmodics to Webcast First Quarter Fiscal 2021 Earnings Conference Call on February 9
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2021 conference call on Tuesday, February 9, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release before the market opens that morning.
Jan 25, 2021 08:25 am ET
12-Month Data from Surmodics’ TRANSCEND Trial Presented at LINC 2021 Event
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 12-month data from its TRANSCEND clinical trial has been presented at the Leipzig Interventional Course (LINC) 2021 virtual event.
Jan 12, 2021 08:05 am ET
Surmodics Announces TRANSCEND Trial 12-Month Data to be Presented at LINC 2021 Virtual Event
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 12-month data from its TRANSCEND clinical trial will be presented at the upcoming Leipzig Interventional Course (LINC) 2021 virtual event. Dr. Kenneth Rosenfield, a principal investigator of the TRANSCEND study, will present as part of a January 25 late-breaking trial session on new data and innovative concepts for treatment of femoral arteries. Preliminary schedule details are provided below:
Nov 09, 2020 08:05 am ET
6-Month Data From the Surmodics Avess™ AV Fistula DCB First-in-Human Study Presented at VIVA 2020
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 6-month data from the AVESS first-in-human (FIH) study of the company’s Avess™ AV Fistula drug-coated balloon (DCB) was shared during a morning session at the Vascular Interventional Advances (VIVA) 2020 virtual conference.
Nov 04, 2020 04:05 pm ET
Surmodics Reports Fourth Quarter Fiscal 2020 Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 fourth quarter ended September 30, 2020.
Oct 27, 2020 08:30 am ET
Surmodics to Webcast Fourth Quarter Fiscal 2020 Earnings Conference Call on November 4
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2020 conference call on Wednesday, November 4, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
Sep 23, 2020 08:30 am ET
Surmodics Receives FDA 510(k) Clearance for Pounce™ Thrombus Retrieval System
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce™ Thrombus Retrieval System.
Aug 05, 2020 04:05 pm ET
Surmodics Receives FDA 510(k) Clearance for Sublime™ Radial Access 0.014 RX PTA Dilatation Catheter
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Sublime™ Radial Access 0.014 Rapid Exchange (RX) Percutaneous Transluminal Angioplasty (PTA) Dilatation Catheter.
Aug 05, 2020 04:05 pm ET
Surmodics Reports Third Quarter Fiscal 2020 Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 third quarter ended June 30, 2020.
Jul 28, 2020 08:30 am ET
Surmodics to Webcast Third Quarter Fiscal 2020 Earnings Conference Call on August 5
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2020 conference call on Wednesday, August 5, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
Jun 08, 2020 08:30 am ET
Surmodics Receives CE Mark for its SurVeil™ Drug Coated Balloon
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has received CE Mark Certification in the European Union for its SurVeil™ drug-coated balloon (DCB).
May 14, 2020 08:30 am ET
Surmodics Names Gordon Weber as Senior Vice President of Legal, General Counsel and Secretary
Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Gordon Weber has joined Surmodics as Senior Vice President of Legal, General Counsel and Secretary effective May 13, 2020.
Apr 29, 2020 04:05 pm ET
Surmodics Reports Second Quarter Fiscal 2020 Results and Provides COVID-19 Pandemic Update
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 second quarter ended March 31, 2020, and suspended its financial guidance for fiscal 2020.
Apr 21, 2020 08:30 am ET
Surmodics to Webcast Second Quarter Fiscal 2020 Earnings Conference Call on April 29
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2020 conference call on Wednesday, April 29, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
Feb 06, 2020 08:35 am ET
Surmodics to Host Virtual Annual Meeting of Shareholders
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 13, at 4 p.m. CT (5:00 p.m. ET), as a virtual meeting.
Feb 05, 2020 04:05 pm ET
Surmodics Reports First Quarter Fiscal 2020 Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 first quarter ended December 31, 2019.
Feb 03, 2020 08:30 am ET
Surmodics Names Nusrath Sultana, MD, as Vice President, Clinical Affairs
Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Nusrath Sultana, MD, has joined Surmodics as Vice President, Clinical Affairs, effective February 3, 2020.
Jan 28, 2020 08:30 am ET
Surmodics to Webcast First Quarter Fiscal 2020 Earnings Conference Call on February 5
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2020 conference call on Wednesday, February 5, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
Oct 31, 2019 04:05 pm ET
Surmodics Reports Fourth Quarter Fiscal 2019 Results and Issues Fiscal 2020 Revenue and EPS Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 fourth quarter ended September 30, 2019, and provided its financial outlook for fiscal 2020.
Oct 29, 2019 08:30 am ET
The Surmodics Sundance™ Sirolimus-Coated Balloon Catheter Earns FDA Breakthrough Device Status
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States Food and Drug Administration (FDA) has designated its Sundance™ sirolimus-coated balloon (SCB) catheter as a Breakthrough Device under the Agency’s Breakthrough Devices Program.
Oct 25, 2019 08:30 am ET
Surmodics to Webcast Fourth Quarter Fiscal 2019 Earnings Conference Call on October 31
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2019 conference call on Thursday, October 31, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
Aug 28, 2019 08:30 am ET
Surmodics Completes Enrollment in Pivotal TRANSCEND Clinical Trial
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has completed enrollment in TRANSCEND, its pivotal clinical trial for the SurVeil™ drug-coated balloon (DCB).
Jul 31, 2019 04:05 pm ET
Surmodics Reports Third Quarter Fiscal 2019 Results and Raises Fiscal 2019 Revenue and EPS Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 third quarter ended June 30, 2019, and updated its financial outlook for fiscal 2019.
Jul 23, 2019 08:30 am ET
Surmodics to Webcast Third Quarter Fiscal 2019 Earnings Conference Call on July 31
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2019 conference call on Wednesday, July 31, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
May 29, 2019 08:30 am ET
Surmodics to Present at Jefferies Healthcare Conference
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies 2019 Healthcare Conference in New York City on Tuesday, June 4, 2019, at 10:30 a.m. ET (9:30 a.m. CT).
May 01, 2019 04:05 pm ET
Surmodics Reports Second Quarter Fiscal 2019 Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 second quarter ended March 31, 2019, and updated its financial outlook for fiscal 2019.
Apr 24, 2019 08:30 am ET
Surmodics to Webcast Second Quarter Fiscal 2019 Earnings Conference Call on May 1
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2019 conference call on Wednesday, May 1, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
Apr 23, 2019 08:30 am ET
Surmodics Sublime™ Guide Sheath Receives FDA 510(k) Approval
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Sublime™ guide sheath.
Apr 17, 2019 11:00 am ET
Surmodics Provides Update Regarding TRANSCEND Clinical Trial
Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, has resumed patient enrollment into its TRANSCEND clinical trial and is nearly 75 percent of the way to its goal of 446 randomized patients.
Apr 02, 2019 08:30 am ET
Surmodics to Present at Needham Healthcare Conference
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will make a presentation to the investment community at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, at 1:30 p.m. ET (12:30 p.m. CT).
Feb 26, 2019 07:50 am ET
Analysis: Positioning to Benefit within Cronos Group, TechnipFMC plc, CalAmp, Liberty Oilfield Services, Teleflex, and Surmodics — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cronos Group Inc. (NASDAQ:CRON), TechnipFMC plc (NYSE:FTI), CalAmp...
Feb 18, 2019 08:30 am ET
Surmodics Announces Appointment of Timothy J. Arens as Chief Financial Officer
Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced the appointment of Timothy J. Arens, Vice President of Corporate Development and Strategy, as the company’s new Chief Financial Officer (CFO), effective immediately.
Feb 05, 2019 08:30 am ET
Surmodics to Host Virtual Annual Meeting of Shareholders
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday, February 13, at 4 p.m. CT (5:00 p.m. ET), as a virtual meeting.
Jan 30, 2019 04:05 pm ET
Surmodics Reports First Quarter Fiscal 2019 Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 first quarter ended December 31, 2018 and updated its financial outlook for fiscal 2019.
Jan 22, 2019 08:30 am ET
Surmodics to Webcast First Quarter Fiscal 2019 Earnings Conference Call on January 30
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2019 conference call on Wednesday, January 30, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
Nov 27, 2018 08:55 am ET
New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 201
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Immunomedics, Inc. (NASDAQ:IMMU), Surmodics, Inc. (NASDAQ:SRDX), PDF...
Nov 09, 2018 07:30 am ET
Surmodics Reports Fourth Quarter Fiscal 2018 Results and Issues Fiscal 2019 Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 fourth quarter ended September 30, 2018, and provided its financial outlook for fiscal 2019.
Nov 06, 2018 06:15 pm ET
12-Month Data from Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2018
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that data from the PREVEIL early feasibility study (EFS) of the company’s SurVeil® drug-coated balloon (DCB) was shared in a late-breaking clinical trial presentation at the Vascular Interventional Advances (VIVA) 2018 conference in Las Vegas. PREVEIL is a prospective, U.S., multi-center, single-arm trial designed to assess the safety and feasibility of the SurVeil DCB in the treatment of subjects with symp
Nov 01, 2018 08:30 am ET
Surmodics Names Teri Sides as Chief Marketing Officer
Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Teri Sides has joined Surmodics as Senior Vice President and Chief Marketing Officer, effective November 1, 2018.
Oct 30, 2018 08:30 am ET
Surmodics to Webcast Fourth Quarter Fiscal 2018 Earnings Conference Call on November 9
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2018 conference call on Friday, November 9, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release earlier that morning.
Oct 16, 2018 08:20 am ET
Investor Expectations to Drive Momentum within Pacific Ethanol, CorVel, Surmodics, Alpha and Omega Semiconductor, MYOS RENS Technology, and Golden Entertainment — Discovering Underlying Factors of Inf
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Pacific Ethanol, Inc. (NASDAQ:PEIX), CorVel Corp. (NASDAQ:CRVL),...
Aug 15, 2018 07:40 am ET
Consolidated Research: 2018 Summary Expectations for Allegiance Bancshares, TG Therapeutics, JELD-WEN Holding, Eagle Bulk Shipping, Bryn Mawr Bank, and Surmodics — Fundamental Analysis, Key Performanc
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Allegiance Bancshares, Inc. (NASDAQ:ABTX), TG Therapeutics, Inc....
Aug 07, 2018 08:30 am ET
Surmodics to Present at 7th Annual Intellisight Investor Conference
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will participate in the 7th Annual Intellisight Conference. The two-day conference, hosted by the CFA Society of Minnesota, will take place this year on Tuesday and Wednesday, August 14 and 15, in Minneapolis.
Aug 06, 2018 07:30 am ET
Surmodics Reports Third Quarter Fiscal 2018 Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 third quarter ended June 30, 2018, and updated its financial outlook for fiscal 2018.
Jul 31, 2018 08:30 am ET
Surmodics IVD Launches Breakthrough MatrixGuard™ Diluent
Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical components for in vitro diagnostic (IVD) tests and microarrays, has announced the launch and immediate availability of MatrixGuard™ Diluent. MatrixGuard Diluent provides assay developers unsurpassed blocking whereby matrix interferences are effectively blocked while the intended assay signal is maintained.
Jul 26, 2018 08:30 am ET
Surmodics to Webcast Third Quarter Fiscal 2018 Earnings Conference Call on August 6
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2018 conference call on Monday, August 6, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release earlier that morning.
May 30, 2018 08:30 am ET
Surmodics to Present at Jefferies 2018 Global Healthcare Conference
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, interim vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies 2018 Global Healthcare Conference in New York City on Friday, June 8, 2018, at 11:30 a.m. ET (10:30 a.m. CT).
May 16, 2018 04:10 pm ET
Biothera Pharmaceuticals Appoints Andrew D.C. LaFrence Chief Financial Officer
Biothera Pharmaceuticals, Inc., announced the appointment of Andrew D.C. LaFrence, CPA as Senior Vice President and Chief Financial Officer, effective May 29.  Biothera Pharmaceuticals is a clinical stage immuno-oncology company developing a novel...
May 16, 2018 04:05 pm ET
Surmodics Announces Leadership Change and Appointment of Interim CFO
Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Andrew LaFrence will resign as Chief Financial Officer (CFO) effective May 25, 2018. Following LaFrence’s departure, Timothy J. Arens, Vice President of Corporate Development and Strategy, will serve as interim CFO. LaFrence has agreed to assist in the orderly transition of his CFO responsibilities. His departure is not related to any disagreement with the company’s accounting principles or practic
May 14, 2018 08:30 am ET
Surmodics Acquires Thrombectomy Technology Assets from Embolitech, Strengthening Peripheral Vascular Whole-Product Solutions Portfolio
Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today it has reached an agreement with Embolitech to acquire an innovative thrombectomy platform technology and related intellectual property with broad potential peripheral vascular applications. Under the agreement, Surmodics will pay $5 million up front, and additional amounts related to various regulatory milestones. The addition of this technology to the Surmodics peripheral vascular pipeline streng
May 02, 2018 07:30 am ET
Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 second quarter, ended March 31, 2018, and raised financial outlook for fiscal 2018.
May 01, 2018 07:30 am ET
Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA COMMS, Westinghouse Air Brake Technologies, and Resource Capital — What Drives Growth in Today's Co
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Vitamin Shoppe, Inc (NYSE:VSI), Surmodics, Inc....
Apr 24, 2018 08:30 am ET
Surmodics to Webcast Second Quarter Fiscal 2018 Earnings Conference Call on May 2
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2018 conference call on Wednesday, May 2, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release earlier that morning.
Apr 23, 2018 08:30 am ET
Surmodics Announces FDA Clearance of a New .018” Low-Profile PTA Balloon Dilation Catheter
Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its .018” Low-Profile percutaneous transluminal angioplasty (PTA) balloon dilation catheter, designed and indicated for a broad range of peripheral vascular applications. The product is the result of the company’s ongoing investment in a pipeline of highly differentiated whole-product solutions. Surmodics expects to make the product
Mar 22, 2018 08:10 am ET
Research Report Identifies Alamo Group, Surmodics, Nicolet Bankshares, Carriage Services, Terra Nitrogen Company, and Waterstone Financial with Renewed Outlook — Fundamental Analysis, Calculating Forw
NEW YORK, March 22, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alamo Group, Inc. (NYSE:ALG), Surmodics, Inc....
Mar 15, 2018 08:30 am ET
Surmodics to Present at Upcoming Investor Conferences
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and information systems and chief financial officer, will be attending two upcoming investor conferences in New York City.
Feb 27, 2018 08:00 am ET
Abbott and Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon
ABBOTT PARK, Ill. and EDEN PRAIRIE, Minn., Feb. 27, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) and Surmodics (NASDAQ: SRDX) today announced that the companies have entered into an agreement whereby Abbott will have exclusive worldwide commercialization rights for Surmodics' SurVeil® drug-coated balloon to treat the superficial femoral artery, which is currently being evaluated in a U.S. pivotal clinical trial. Separately, Abbott also received options to negotiate agreements for Surmodics' below-the-knee and arteriovenous (AV) fistula drug-coated balloon products, which are currently in pre-clin
Feb 13, 2018 08:30 am ET
Surmodics to Host Virtual Annual Meeting of Shareholders
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday, February 21, at 4:00 p.m. CT (5:00 p.m. ET), as a virtual meeting.
Feb 08, 2018 07:30 am ET
Surmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 first quarter, ended December 31, 2017, and updated financial outlook for fiscal 2018.
Jan 30, 2018 08:00 am ET
Surmodics to Webcast First Quarter Fiscal 2018 Earnings Conference Call on February 8
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2018 conference call on Thursday, February 8, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release earlier that morning.
Jan 22, 2018 08:00 am ET
Surmodics Receives 510(K) Clearance for Telemark™ Coronary/Peripheral Support Microcatheter from the U.S. Food and Drug Administration
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Telemark™ .014” coronary and peripheral support microcatheter. The Company is making this product available for U.S. distribution in the coming months.
Jan 19, 2018 08:00 am ET
Detailed Research: Economic Perspectives on Basic Energy Services, Intercept Pharmaceuticals, Natus Medical, Surmodics, EnviroStarm, and Nicolet Bankshares — What Drives Growth in Today's Competitive
NEW YORK, Jan. 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Basic Energy Services, Inc. (NYSE:BAS), Intercept...
Nov 08, 2017 07:30 am ET
Surmodics Reports Fourth Quarter Fiscal 2017 Results and Provides Fiscal 2018 Guidance
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 fourth quarter, ended September 30, 2017 and financial outlook for fiscal 2018.
Oct 26, 2017 04:05 pm ET
Surmodics to Present at Canaccord Genuity Medical Technologies and Diagnostics Forum
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and information systems and chief financial officer, will make a presentation to the investment community at the Canaccord Genuity Medical Technologies and Diagnostics Forum in New York City on Thursday, November 9, 2017, at 9 a.m. ET (8 a.m. CT).
Oct 26, 2017 08:00 am ET
Surmodics to Webcast Fourth Quarter 2017 Earnings Conference Call on November 8
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter 2017 conference call on Wednesday, November 8, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release earlier that morning.
Oct 23, 2017 08:00 am ET
Surmodics Announces First Patient Enrolled in TRANSCEND Pivotal Clinical Trial for SurVeil® Drug-Coated Balloon
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first patient in TRANSCEND, the pivotal clinical trial for the SurVeil® drug-coated balloon (DCB). The randomized trial will evaluate the SurVeil DCB for treatment for peripheral artery disease (PAD) in the upper leg compared to a commercially available DCB treatment. Up to 446 patients will be randomized 1:1 to receive either the SurVeil DCB or Medtronic’s IN.PACT® Admiral® DCB at

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.